[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-and-maxillofacial-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-and-maxillofacial-conditions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634185","phase-3-biologic-augmentation-of-tmj-arthroscopy-using-bmac-100634185",false,"NCT07536399","Biologic Augmentation of TMJ Arthroscopy Using BMAC","Biologic Augmentation of Temporomandibular Joint Arthroscopy Using Bone Marrow Aspirate Concentrate (BMAC): A Proposed Clinical Trial","Inclusion Criteria:\n\n1. Participant is at least 18 years of age and not older than 75 years of age\n2. Participant is willing and able to provide written informed consent to participant in this study\n3. Participant has symptoms of TMJ arthralgia (pain) with significant temporomandibular joint pain and dysfunction despite at least 30 days of conservative therapy (NSAIDS, muscle relaxants, bite splints, PT, warm compresses, soft diet, etc.)\n4. Participant has baseline pain of ≥30 on a 100mm visual analog scale (VAS)\n\nExclusion Criteria:\n\n1. Participant has not competed at least 30 days of conservative therapy\n2. Participant was diagnosed with central or neuropathic pain disorder\n3. Participant has a primary diagnosis of myofascial pain\n4. Participant has fibromyalgia\n5. Participant is pregnant or breastfeeding\n6. Participant had traumatic injury to the masticatory muscles or temporomandibular joint within 12 months of screening\n7. Participant who has the following contraindications to MRI:\n\n   * Electrical implants such as cardiac pacemakers or perfusion pumps\n   * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants\n   * History of seizures\n   * Patients with GFR \\\u003C 15 ml\u002Fmin\u002F1.73m2 or who are on dialysis will be excluded from the study.\n   * Allergy to contrast die","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn about the efficacy of using Bone Marrow Aspirate Concentrate (BMAC) during temporomandibular joint (TMJ) arthroscopy compared to standard arthroscopic procedures with corticosteroid (CS) injections in patients with pain (arthralgia) of the temporomandibular joint (TMJ) that has failed to respond to conservative treatment. The main question it aims to answer:\n\nDoes BMAC injection reduce the amount of inflammation and structural damage in the TMJ? Researchers will compare BMAC injection to corticosteroid injections see if BMAC injection helps .\n\nParticipants will :\n\n* Be randomized to receive either BMAC or CS injection during TMJ arthroscopy\n* Visit the clinic for 3 follow up visits over 6 months and answer questionnaires\n* have 2 MRIs of their jaw",[27,28,29,30],"TMJ - Oral &Maxillofacial Surgery","Oral and Maxillofacial Conditions","TMJ Pain","TMJ Arthralgia",[32,33,34,35,36,37],"TMJ pain","Oral and maxillofacial conditions","TMJ arthroscopy","bone marrow aspirate concentrate","BMAC","steroid","NOT_YET_RECRUITING","2026-04-10",{"date":41,"type":42},"2026-04-17","ACTUAL",{"date":44,"type":21},"2026-04",{"date":46,"type":21},"2028-06",{"name":48,"class":49},"Weill Medical College of Cornell University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":50},"100594807","biological-waste-sample-collection-for-progress-in-oral-and-maxillofacial-research-100594807","NCT07024251","BIOlogical Waste Sample Collection for Progress in Oral and MAXillofacial Research","BIO-MAX","Inclusion Criteria:\n\n* males and females\n* ≥18 years old\n* patients undergoing either routine oral clinical examination or elective oral and maxillofacial surgery at IRCCS Ospedale Galeazzi - Sant'Ambrogio\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* inability to sign the Informed Consent\n* positivity to virological tests (HIV, HCV, HBV, TPHA), if serological analysis is required\n* pregnancy and breast feeding with declaration of patient",true,{"count":60,"type":21},383,"OBSERVATIONAL","The BIO-MAX (BIOlogical waste sample collection for progress in oral and MAXillofacial research) study, led by IRCCS Ospedale Galeazzi-Sant'Ambrogio, is a five-year observational research project aimed at improving the understanding and treatment of oral and maxillofacial conditions.\n\nResearchers are collecting and analyzing biological samples-such as saliva, blood, and tissues typically discarded during dental and surgical procedures-from adult patients visiting the hospital for oral exams or surgery. A key focus is the study of salivary irisin, a promising biomarker linked to diseases like diabetes and heart disease. By examining how irisin levels vary with age, gender, lifestyle, and oral health, the team hopes to establish baseline values and better understand its diagnostic potential.\n\nIn addition to irisin analysis, the study will explore other waste tissues to uncover disease mechanisms, identify new biomarkers, and test future therapies using patient-derived laboratory models. Overall, BIO-MAX seeks to enhance diagnostics, improve patient care, and pave the way for innovative treatments in oral and maxillofacial medicine.",[28],"RECRUITING","2025-06-12",{"date":67,"type":42},"2025-06-17",{"date":69,"type":42},"2025-05-16",{"date":71,"type":21},"2030-05",{"name":73,"class":49},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio"]